Sruthi S. Balakrishnan | Sep 1, 2021 | 10+ min read
A year and a half into the pandemic, the long-term effects of SARS-CoV-2 infection are garnering more research attention as millions of long COVID patients emerge.
A comparison of interferon-related genes across 20 primate genomes reveals differences in the speed at which they evolve and new targets for antiviral discovery efforts.
The World Health Organization–led program will promote equity in addition to facilitating access to samples, a WHO official involved in the project tells The Scientist.
New genomic analyses reveal that piscine orthoreovirus first came to the Pacific in 1989, around the same time that salmon farms in the area started importing Atlantic salmon eggs from Europe.
A letter signed by 18 researchers argues that hypotheses about zoonotic spillover or accidental lab release both “remain viable” in the absence of additional evidence.
By avoiding the production of antibodies, something vaccines ordinarily induce, the immunization sidesteps the problem of antibody-dependent enhancement, which can amplify infection by a similar virus and is known to occur with dengue and Zika.
While some experts speculate the variant could be partially responsible for India’s current surge in SARS-CoV-2 infections, information about the effects of its mutations is only beginning to emerge.
In a trio of studies, researchers follow up on a 40-year-old finding that certain bacteriophages replace adenine with so-called diaminopurine, perhaps to avoid host degradation.
Researchers involved in a long-term project to identify viruses of concern have now assessed the risk factors that could help forecast which pathogens are the most likely to spillover from wildlife to people.
Martha Nelson of the National Institute of Allergy and Infectious Diseases talks about the need to balance data sharing and patient privacy concerns when tracking the spread of variants.